Proposals from the Board of Directors in Item 6 of the agenda were adopted as follows:
-- Proposal for the annual report and interim reports to be prepared and presented in English. -- Proposal for company announcements to be prepared and published in English. -- Proposal for approval of Remuneration Policy and Guidelines for Incentive-based remuneration. -- Proposal for renewal of the authorization to issue convertible bonds.
Thomas Magnussen, Torben A. Nielsen and Niels Christian Nielsen offered themselves for re-election and were re-elected. In addition, Kirsten Drejer was elected as a new board member. Immediately after the Annual General Meeting, the Board of Directors elected Thomas Magnussen as its chairman and Torben A. Nielsen as its vice chairman.
PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab was re-elected as the Company's auditor.
Hellerup, April 21, 2017
The Board of Directors
For further information, please contact:
Peter Morch Eriksen, CEO
Gry Husby Larsen, General Counsel
Telephone +45 45 29 00 00, e-mail email@example.com
BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Our pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the Nasdaq Copenhagen stock exchange.